BioPharmaPT
← All reports

Astellas Pharma Inc. — Vyloy EMA EPAR public assessment report (EMEA/H/C/005868, 2024)

Astellas Pharma Inc. · 2024 · EMA EPAR public assessment report · company profile →

Report summary

This EMA report details the assessment of Vyloy (zolbetuximab) for first-line treatment of HER2-negative, CLDN18.2-positive gastric or gastro-oesophageal junction adenocarcinoma. It covers manufacturing, quality control, and non-clinical aspects, including zolbetuximab's mechanism of action and anti-tumor activity. Preclinical studies showed efficacy in combination with chemotherapy. Clinical studies (SPOTLIGHT, GLOW) demonstrated significant improvements in progression-free and overall survival. Pharmacokinetic analyses informed dosing, while safety data highlighted gastrointestinal toxicities, particularly nausea and vomiting. Despite these, a positive benefit-risk assessment led to approval.

Key findings — cited to the page

Nausea Grade ≥ 3 (zolbetuximab + mFOLFOX6 or CAPOX)12.6 % · p.230
Nausea Grade ≥ 3 (Placebo + mFOLFOX6 or CAPOX)4.6 % · p.230
Grade ≥3 AE (zolbetuximab + mFOLFOX6 or CAPOX)80.1 % · p.230
Grade ≥3 AE (Z/P related) (Placebo + mFOLFOX6 or CAPOX)29.2 % · p.230
Vomiting Grade ≥ 3 (zolbetuximab + mFOLFOX6 or CAPOX)14.3 % · p.230
Vomiting Grade ≥ 3 (Placebo + mFOLFOX6 or CAPOX)4.7 % · p.230
predicted probability of Grade 3 AEs at upper end of Cmax_1st distributionless than 40 % · p.73
predicted probability of Grade 3 AEs at 50th percentile of Cmax_1st20 % · p.73
Grade ≥3 AE (Placebo + mFOLFOX6 or CAPOX)74.0 % · p.230
Grade ≥3 AE (Z/P related) (zolbetuximab + mFOLFOX6 or CAPOX)46.3 % · p.230
TEAE with CTCAE Grade ≥ 3403 nSPOTLIGHT/GLOW · p.59
TEAE with CTCAE Grade ≥ 324 nSPOTLIGHT/GLOW · p.59

Source: Astellas Pharma Inc. · License: EMA - reuse permitted with acknowledgement. Summary and findings are extracted from the published document; every figure cites its page. Informational only — not investment advice. Explore the Oncology library →

Astellas Pharma Inc. — Vyloy EMA EPAR public assessment report (EMEA/H/C/005868, 2024) — Summary & Key Findings | BioPharmaPT